BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010;1:e105. [PMID: 21368878 DOI: 10.1038/cddis.2010.85] [Cited by in Crossref: 146] [Cited by in F6Publishing: 142] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Li XH, Qu JQ, Yi H, Zhang PF, Yi HM, Wan XX, He QY, Ye X, Yuan L, Zhu JF, Li JY, Xiao ZQ. Integrated analysis of differential miRNA and mRNA expression profiles in human radioresistant and radiosensitive nasopharyngeal carcinoma cells. PLoS One 2014;9:e87767. [PMID: 24498188 DOI: 10.1371/journal.pone.0087767] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
2 Ayub SG, Kaul D, Ayub T. Microdissecting the role of microRNAs in the pathogenesis of prostate cancer. Cancer Genet 2015;208:289-302. [PMID: 26004033 DOI: 10.1016/j.cancergen.2015.02.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
3 Dong Z, Zhong Z, Yang L, Wang S, Gong Z. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Letters 2014;343:249-57. [DOI: 10.1016/j.canlet.2013.09.034] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
4 Ramassone A, Pagotto S, Veronese A, Visone R. Epigenetics and MicroRNAs in Cancer. Int J Mol Sci 2018;19:E459. [PMID: 29401683 DOI: 10.3390/ijms19020459] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 25.3] [Reference Citation Analysis]
5 Gandellini P, Giannoni E, Casamichele A, Taddei ML, Callari M, Piovan C, Valdagni R, Pierotti MA, Zaffaroni N, Chiarugi P. miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. Antioxid Redox Signal. 2014;20:1045-1059. [PMID: 23924028 DOI: 10.1089/ars.2013.5292] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
6 Fuse M, Kojima S, Enokida H, Chiyomaru T, Yoshino H, Nohata N, Kinoshita T, Sakamoto S, Naya Y, Nakagawa M, Ichikawa T, Seki N. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J Hum Genet 2012;57:691-9. [PMID: 22854542 DOI: 10.1038/jhg.2012.95] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 8.4] [Reference Citation Analysis]
7 Bosutti A, Zanconati F, Grassi G, Dapas B, Passamonti S, Scaggiante B. Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals. Anticancer Agents Med Chem 2016;16:1385-402. [PMID: 27109021 DOI: 10.2174/1871520616666160425105257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
8 Li X, Pan JH, Song B, Xiong EQ, Chen ZW, Zhou ZS, Su YP. Suppression of CX43 expression by miR-20a in the progression of human prostate cancer. Cancer Biol Ther 2012;13:890-8. [PMID: 22785209 DOI: 10.4161/cbt.20841] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
9 Agostini M, Tucci P, Melino G. Cell death pathology: Perspective for human diseases. Biochemical and Biophysical Research Communications 2011;414:451-5. [DOI: 10.1016/j.bbrc.2011.09.081] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
10 Pashaei E, Pashaei E, Ahmady M, Ozen M, Aydin N. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy. PLoS One 2017;12:e0179543. [PMID: 28651018 DOI: 10.1371/journal.pone.0179543] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 14.8] [Reference Citation Analysis]
11 Maugeri-Saccà M, Coppola V, Bonci D, De Maria R. MicroRNAs and prostate cancer: from preclinical research to translational oncology. Cancer J 2012;18:253-61. [PMID: 22647362 DOI: 10.1097/PPO.0b013e318258b5b6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
12 Khanmi K, Ignacimuthu S, Paulraj MG. MicroRNA in prostate cancer. Clin Chim Acta 2015;451:154-60. [PMID: 26415820 DOI: 10.1016/j.cca.2015.09.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
13 Lee MR, Mantel C, Lee SA, Moon SH, Broxmeyer HE. MiR-31/SDHA Axis Regulates Reprogramming Efficiency through Mitochondrial Metabolism. Stem Cell Reports 2016;7:1-10. [PMID: 27346679 DOI: 10.1016/j.stemcr.2016.05.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
14 Fang YX, Gao WQ. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 2014;33:135-47. [PMID: 23455326 DOI: 10.1038/onc.2013.54] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 10.1] [Reference Citation Analysis]
15 Ma X, Zou L, Li X, Chen Z, Lin Q, Wu X. MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer. Biomedicine & Pharmacotherapy 2018;99:445-50. [DOI: 10.1016/j.biopha.2018.01.088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
16 Gandellini P, Profumo V, Casamichele A, Fenderico N, Borrelli S, Petrovich G, Santilli G, Callari M, Colecchia M, Pozzi S, De Cesare M, Folini M, Valdagni R, Mantovani R, Zaffaroni N. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ 2012;19:1750-60. [PMID: 22555458 DOI: 10.1038/cdd.2012.56] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
17 Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer 2016;15:70. [PMID: 27832783 DOI: 10.1186/s12943-016-0556-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 10.6] [Reference Citation Analysis]
18 Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 2012;6:458-472. [PMID: 22578566 DOI: 10.1016/j.molonc.2012.03.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 11.7] [Reference Citation Analysis]
19 Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget 2014;5:824-40. [PMID: 24583788 DOI: 10.18632/oncotarget.1776] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
20 Ma H, Cao W, Ding M. MicroRNA-31 weakens cisplatin resistance of medulloblastoma cells via NF-κB and PI3K/AKT pathways. Biofactors 2020;46:831-8. [PMID: 32027070 DOI: 10.1002/biof.1616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Wen S, Niu Y, Lee SO, Chang C. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat Rev. 2014;40:31-40. [PMID: 23993415 DOI: 10.1016/j.ctrv.2013.07.008] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 6.8] [Reference Citation Analysis]
22 Hartman ML, Czyz M. BCL-w: apoptotic and non-apoptotic role in health and disease. Cell Death Dis 2020;11:260. [PMID: 32317622 DOI: 10.1038/s41419-020-2417-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
23 Qin AY, Zhang XW, Liu L, Yu JP, Li H, Wang SZ, Ren XB, Cao S. MiR-205 in cancer: an angel or a devil? Eur J Cell Biol. 2013;92:54-60. [PMID: 23279926 DOI: 10.1016/j.ejcb.2012.11.002] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 10.1] [Reference Citation Analysis]
24 Wang Z, Xie Q, Yu Z, Zhou H, Huang Y, Bi X, Wang Y, Shi W, Sun H, Gu P, Fan X. A regulatory loop containing miR-26a, GSK3β and C/EBPα regulates the osteogenesis of human adipose-derived mesenchymal stem cells. Sci Rep 2015;5:15280. [PMID: 26469406 DOI: 10.1038/srep15280] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
25 Wang Y, Yuan Y, Gao Y, Li X, Tian F, Liu F, Du R, Li P, Wang F, Xu S, Wu X, Wang C. MicroRNA-31 regulating apoptosis by mediating the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in treatment of spinal cord injury. Brain Dev 2019;41:649-61. [PMID: 31036380 DOI: 10.1016/j.braindev.2019.04.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
26 Li M, Chen W, Zhang H, Zhang Y, Ke F, Wu X, Zhang Y, Weng M, Liu Y, Gong W. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Oncotarget 2016;7:83060-70. [PMID: 27825112 DOI: 10.18632/oncotarget.13067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
27 O'Kelly F, Marignol L, Meunier A, Lynch TH, Perry AS, Hollywood D. MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol 2012;9:397-407. [PMID: 22613932 DOI: 10.1038/nrurol.2012.104] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
28 Nair S, Kong AT. Architecture of Signature miRNA Regulatory Networks in Cancer Chemoprevention. Curr Pharmacol Rep 2015;1:89-101. [DOI: 10.1007/s40495-014-0014-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H, Melnick AM, Elemento O, Demichelis F, Rubin MA. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 2013;73:1232-44. [PMID: 23233736 DOI: 10.1158/0008-5472.CAN-12-2968] [Cited by in Crossref: 114] [Cited by in F6Publishing: 69] [Article Influence: 12.7] [Reference Citation Analysis]
30 Kopczyńska E. Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel. Contemp Oncol (Pozn) 2015;19:423-7. [PMID: 26843836 DOI: 10.5114/wo.2015.56648] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
31 Lv J, Xia K, Xu P, Sun E, Ma J, Gao S, Zhou Q, Zhang M, Wang F, Chen F, Zhou P, Fu Z, Xie H. miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014;68:935-42. [PMID: 25451164 DOI: 10.1016/j.biopha.2014.09.011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
32 Singh PK, Campbell MJ. The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer. Cancers (Basel) 2013;5:998-1019. [PMID: 24202331 DOI: 10.3390/cancers5030998] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
33 Lin N, Zhou Y, Lian X, Tu Y. MicroRNA-31 functions as an oncogenic microRNA in cutaneous squamous cell carcinoma cells by targeting RhoTBT1. Oncol Lett 2017;13:1078-82. [PMID: 28454216 DOI: 10.3892/ol.2017.5554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
34 Doldi V, El Bezawy R, Zaffaroni N. MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. Cancers (Basel) 2021;13:2380. [PMID: 34069147 DOI: 10.3390/cancers13102380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hu J, Wu X, Yang C, Rashid K, Ma C, Hu M, Ding Q, Jiang H. Anticancer effect of icaritin on prostate cancer via regulating miR-381-3p and its target gene UBE2C. Cancer Med 2019;8:7833-45. [PMID: 31646760 DOI: 10.1002/cam4.2630] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
36 Akoto T, Bhagirath D, Saini S. MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer. Cancer Drug Resist 2020;3:804-18. [PMID: 33426506 DOI: 10.20517/cdr.2020.30] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Razdan A, de Souza P, Roberts TL. Role of MicroRNAs in Treatment Response in Prostate Cancer. Curr Cancer Drug Targets 2018;18:929-44. [PMID: 29644941 DOI: 10.2174/1568009618666180315160125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
38 Busbee PB, Nagarkatti M, Nagarkatti PS. Natural indoles, indole-3-carbinol (I3C) and 3,3'-diindolylmethane (DIM), attenuate staphylococcal enterotoxin B-mediated liver injury by downregulating miR-31 expression and promoting caspase-2-mediated apoptosis. PLoS One. 2015;10:e0118506. [PMID: 25706292 DOI: 10.1371/journal.pone.0118506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
39 Li F, Mahato RI. MicroRNAs and drug resistance in prostate cancers. Mol Pharm 2014;11:2539-52. [PMID: 24742219 DOI: 10.1021/mp500099g] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
40 Altschuler J, Stockert JA, Kyprianou N. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. Int J Mol Sci 2021;22:2100. [PMID: 33672595 DOI: 10.3390/ijms22042100] [Reference Citation Analysis]
41 Rizzo M, Berti G, Russo F, Evangelista M, Pellegrini M, Rainaldi G. The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate Cancer. Int J Genomics 2017;2017:5214806. [PMID: 29085832 DOI: 10.1155/2017/5214806] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
42 Shi X, Xiao L, Mao X, He J, Ding Y, Huang J, Peng C, Xu Z. miR-205-5p Mediated Downregulation of PTEN Contributes to Cisplatin Resistance in C13K Human Ovarian Cancer Cells. Front Genet 2018;9:555. [PMID: 30510566 DOI: 10.3389/fgene.2018.00555] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
43 Zhang Q, Sun M, Zhou S, Guo B. Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6. Cell Death Discov 2016;2:16036. [PMID: 27551526 DOI: 10.1038/cddiscovery.2016.36] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
44 Kgatle MM, Kalla AA, Islam MM, Sathekge M, Moorad R. Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy. Prostate Cancer 2016;2016:5653862. [PMID: 27891254 DOI: 10.1155/2016/5653862] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
45 Biersack B. Relations between approved platinum drugs and non-coding RNAs in mesothelioma. Noncoding RNA Res 2018;3:161-73. [PMID: 30809599 DOI: 10.1016/j.ncrna.2018.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
46 Ehsani M, David FO, Baniahmad A. Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer. Cancers (Basel) 2021;13:1534. [PMID: 33810413 DOI: 10.3390/cancers13071534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Massillo C, Dalton GN, Farré PL, De Luca P, De Siervi A. Implications of microRNA dysregulation in the development of prostate cancer. Reproduction 2017;154:R81-97. [DOI: 10.1530/rep-17-0322] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
48 Zhao Z, Weickmann S, Jung M, Lein M, Kilic E, Stephan C, Erbersdobler A, Fendler A, Jung K. A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature. Cancers (Basel) 2019;11:E1603. [PMID: 31640261 DOI: 10.3390/cancers11101603] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
49 Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S, Yentur S, Creighton CJ, Ittmann M, Ozen M. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. Int J Cancer 2015;136:875-9. [PMID: 24976077 DOI: 10.1002/ijc.29054] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
50 Park KS, Moon YW, Raffeld M, Lee DH, Wang Y, Giaccone G. High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. Lung Cancer 2018;116:38-45. [PMID: 29413049 DOI: 10.1016/j.lungcan.2017.12.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
51 Nagesh PKB, Chowdhury P, Hatami E, Boya VKN, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM. miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy. Cancers (Basel) 2018;10:E289. [PMID: 30149628 DOI: 10.3390/cancers10090289] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
52 Kojima S, Goto Y, Naya Y. The roles of microRNAs in the progression of castration-resistant prostate cancer. J Hum Genet 2017;62:25-31. [PMID: 27278789 DOI: 10.1038/jhg.2016.69] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
53 Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, Fullen DR, Johnson TM, Giordano TJ, Palanisamy N, Chinnaiyan AM. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012;3:1011-25. [PMID: 22948084 DOI: 10.18632/oncotarget.622] [Cited by in Crossref: 106] [Cited by in F6Publishing: 95] [Article Influence: 13.3] [Reference Citation Analysis]
54 Bucur O, Stancu AL, Khosravi-Far R, Almasan A. Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. Cell Death Dis 2012;3:e263. [PMID: 22297295 DOI: 10.1038/cddis.2012.2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
55 Ganju A, Yallapu MM, Khan S, Behrman SW, Chauhan SC, Jaggi M. Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resist Updat 2014;17:13-23. [PMID: 24853766 DOI: 10.1016/j.drup.2014.04.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
56 Xu W, Allbritton N, Lawrence DS. SRC kinase regulation in progressively invasive cancer. PLoS One 2012;7:e48867. [PMID: 23145001 DOI: 10.1371/journal.pone.0048867] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
57 Kalogirou C, Linxweiler J, Schmucker P, Snaebjornsson MT, Schmitz W, Wach S, Krebs M, Hartmann E, Puhr M, Müller A, Spahn M, Seitz AK, Frank T, Marouf H, Büchel G, Eckstein M, Kübler H, Eilers M, Saar M, Junker K, Röhrig F, Kneitz B, Rosenfeldt MT, Schulze A. MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun 2021;12:5066. [PMID: 34417456 DOI: 10.1038/s41467-021-25325-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Jung JE, Lee JY, Kim IR, Park SM, Kang JW, Kim YH, Park HR, Lee JH. MicroRNA-31 Regulates Expression of Wntless in Both Drosophila melanogaster and Human Oral Cancer Cells. Int J Mol Sci 2020;21:E7232. [PMID: 33007980 DOI: 10.3390/ijms21197232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z, Cao Y. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res 2013;32:96. [PMID: 24261995 DOI: 10.1186/1756-9966-32-96] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 9.6] [Reference Citation Analysis]
60 Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW, Kim YT. MicroRNA profiling of a CD133(+) spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line. BMC Med Genomics 2012;5:18. [PMID: 22643117 DOI: 10.1186/1755-8794-5-18] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
61 Pinatel EM, Orso F, Penna E, Cimino D, Elia AR, Circosta P, Dentelli P, Brizzi MF, Provero P, Taverna D. miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. PLoS One 2014;9:e84859. [PMID: 24400121 DOI: 10.1371/journal.pone.0084859] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
62 Ozen M, Karatas OF, Gulluoglu S, Bayrak OF, Sevli S, Guzel E, Ekici ID, Caskurlu T, Solak M, Creighton CJ, Ittmann M. Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression. Cancer Invest 2015;33:251-8. [PMID: 25951106 DOI: 10.3109/07357907.2015.1025407] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 8.5] [Reference Citation Analysis]
63 Ghaffari SH, Bashash D. Reciprocal Interconnection of miRNome-Epigenome in Cancer Pathogenesis and Its Therapeutic Potential. In: Mehdipour P, editor. Epigenetics Territory and Cancer. Dordrecht: Springer Netherlands; 2015. pp. 101-35. [DOI: 10.1007/978-94-017-9639-2_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Hervouet E, Cheray M, Vallette FM, Cartron PF. DNA methylation and apoptosis resistance in cancer cells. Cells 2013;2:545-73. [PMID: 24709797 DOI: 10.3390/cells2030545] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
65 Profumo V, Forte B, Percio S, Rotundo F, Doldi V, Ferrari E, Fenderico N, Dugo M, Romagnoli D, Benelli M, Valdagni R, Dolfini D, Zaffaroni N, Gandellini P. LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation. Nat Commun 2019;10:307. [PMID: 30659180 DOI: 10.1038/s41467-018-08153-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
66 Hagman Z, Haflidadóttir BS, Ceder JA, Larne O, Bjartell A, Lilja H, Edsjö A, Ceder Y. miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 2013;108:1668-76. [PMID: 23571738 DOI: 10.1038/bjc.2013.131] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 9.6] [Reference Citation Analysis]
67 Lo UG, Yang D, Hsieh JT. The role of microRNAs in prostate cancer progression. Transl Androl Urol 2013;2:228-41. [PMID: 26813625 DOI: 10.3978/j.issn.2223-4683.2013.08.01] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
68 Laurila EM, Kallioniemi A. The diverse role of miR-31 in regulating cancer associated phenotypes. Genes Chromosomes Cancer. 2013;52:1103-1113. [PMID: 23999990 DOI: 10.1002/gcc.22107] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
69 Xie Q, Wang Z, Zhou H, Yu Z, Huang Y, Sun H, Bi X, Wang Y, Shi W, Gu P, Fan X. The role of miR-135-modified adipose-derived mesenchymal stem cells in bone regeneration. Biomaterials 2016;75:279-94. [DOI: 10.1016/j.biomaterials.2015.10.042] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 13.0] [Reference Citation Analysis]
70 Lu Z, Nian Z, Jingjing Z, Tao L, Quan L. MicroRNA-424/E2F6 feedback loop modulates cell invasion, migration and EMT in endometrial carcinoma. Oncotarget 2017;8:114281-91. [PMID: 29371986 DOI: 10.18632/oncotarget.23218] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
71 Cui M, Xiao Z, Sun B, Wang Y, Zheng M, Ye L, Zhang X. Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4. Biochem Biophys Res Commun 2014;445:651-5. [PMID: 24576478 DOI: 10.1016/j.bbrc.2014.02.068] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
72 Guzel E, Karatas OF, Duz MB, Solak M, Ittmann M, Ozen M. Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. Prostate 2014;74:1498-505. [PMID: 25175483 DOI: 10.1002/pros.22867] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
73 Grespi F, Landré V, Molchadsky A, Di Daniele N, Marsella LT, Melino G, Rotter V. Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells. Cell Death Dis 2016;7:e2567. [PMID: 28032868 DOI: 10.1038/cddis.2016.419] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
74 Liep J, Rabien A, Jung K. Feedback networks between microRNAs and epigenetic modifications in urological tumors. Epigenetics 2012;7:315-25. [PMID: 22414795 DOI: 10.4161/epi.19464] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
75 Niu XB, Fu GB, Wang L, Ge X, Liu WT, Wen YY, Sun HR, Liu LZ, Wang ZJ, Jiang BH. Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer. Oncotarget 2017;8:107157-66. [PMID: 29291019 DOI: 10.18632/oncotarget.22362] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
76 Kim JS, Yu SK, Lee MH, Park MG, Park E, Kim SG, Lee SY, Kim CS, Kim HJ, Chun HS, Chun SW, Kim DK. MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells. Mol Cells 2013;35:17-24. [PMID: 23212344 DOI: 10.1007/s10059-013-2154-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
77 Kanwal R, Plaga AR, Liu X, Shukla GC, Gupta S. MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer Letters 2017;407:9-20. [DOI: 10.1016/j.canlet.2017.08.011] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 17.3] [Reference Citation Analysis]
78 Amelio I, Melino G, Knight RA. Cell death pathology: cross-talk with autophagy and its clinical implications. Biochem Biophys Res Commun. 2011;414:277-281. [PMID: 21963447 DOI: 10.1016/j.bbrc.2011.09.080] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 5.8] [Reference Citation Analysis]
79 Romero-Garcia S, Prado-Garcia H, Carlos-Reyes A. Role of DNA Methylation in the Resistance to Therapy in Solid Tumors. Front Oncol 2020;10:1152. [PMID: 32850327 DOI: 10.3389/fonc.2020.01152] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
80 Zhang Q, Padi SK, Tindall DJ, Guo B. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis 2014;5:e1486. [PMID: 25341040 DOI: 10.1038/cddis.2014.454] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
81 Wang YL, Wu S, Jiang B, Yin FF, Zheng SS, Hou SC. Role of MicroRNAs in Prostate Cancer Pathogenesis. Clin Genitourin Cancer 2015;13:261-70. [PMID: 25733057 DOI: 10.1016/j.clgc.2015.01.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
82 Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen LN, Li X, Berry DL, Kallakury BV, Chauhan SC, Collins SP, Suy S, Kumar D. MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. PLoS One 2013;8:e76994. [PMID: 24167554 DOI: 10.1371/journal.pone.0076994] [Cited by in Crossref: 108] [Cited by in F6Publishing: 111] [Article Influence: 13.5] [Reference Citation Analysis]
83 Karatas OF, Guzel E, Suer I, Ekici ID, Caskurlu T, Creighton CJ, Ittmann M, Ozen M. miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. PLoS One. 2014;9:e98675. [PMID: 24967583 DOI: 10.1371/journal.pone.0098675] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 7.4] [Reference Citation Analysis]
84 Conforti F, Sayan AE, Sreekumar R, Sayan BS. Regulation of p73 activity by post-translational modifications. Cell Death Dis 2012;3:e285. [PMID: 22419114 DOI: 10.1038/cddis.2012.27] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
85 Zhou F, Zhang F, Zhou C, Liang M, Cai Z, Lv H, Li W, Wei X. Human antigen R and drug resistance in tumors. Invest New Drugs 2019;37:1107-16. [DOI: 10.1007/s10637-018-00723-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
86 Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, Pützer BM. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012;11:3067-78. [PMID: 22871739 DOI: 10.4161/cc.21476] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.8] [Reference Citation Analysis]
87 Hasegawa T, Adachi R, Iwakata H, Takeno T, Sato K, Sakamaki T. ErbB2 signaling epigenetically suppresses microRNA-205 transcription via Ras/Raf/MEK/ERK pathway in breast cancer. FEBS Open Bio 2017;7:1154-65. [PMID: 28781955 DOI: 10.1002/2211-5463.12256] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
88 Bryzgunova OE, Konoshenko MY, Laktionov PP. MicroRNA-guided gene expression in prostate cancer: Literature and database overview. J Gene Med 2018;20:e3016. [DOI: 10.1002/jgm.3016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
89 Wang H, Liu W, Black S, Turner O, Daniel JM, Dean-Colomb W, He QP, Davis M, Yates C. Kaiso, a transcriptional repressor, promotes cell migration and invasion of prostate cancer cells through regulation of miR-31 expression. Oncotarget 2016;7:5677-89. [PMID: 26734997 DOI: 10.18632/oncotarget.6801] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
90 Knight RA, Melino G. Cell death in disease: from 2010 onwards. Cell Death Dis 2011;2:e202. [PMID: 21881604 DOI: 10.1038/cddis.2011.89] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
91 Zheng Y, Sun Y, Liu Y, Zhang X, Li F, Li L, Wang J. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway. Biochemical and Biophysical Research Communications 2018;503:2451-8. [DOI: 10.1016/j.bbrc.2018.06.175] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
92 Casanova-Salas I, Rubio-Briones J, Fernández-Serra A, López-Guerrero JA. miRNAs as biomarkers in prostate cancer. Clin Transl Oncol 2012;14:803-11. [PMID: 22855165 DOI: 10.1007/s12094-012-0877-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
93 Mohamad Hanif EA. Dysregulation of non-histone molecule miR205 and LRG1 post-transcriptional de-regulation by SETD1A in triple negative breast cancer. Mol Biol Rep 2019;46:6617-24. [DOI: 10.1007/s11033-019-05079-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Ween MP, Armstrong MA, Oehler MK, Ricciardelli C. The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit Rev Oncol Hematol 2015;96:220-56. [PMID: 26100653 DOI: 10.1016/j.critrevonc.2015.05.012] [Cited by in Crossref: 90] [Cited by in F6Publishing: 87] [Article Influence: 15.0] [Reference Citation Analysis]
95 Lin G, Xu K. [Advances in tumor chemo-resistance regulated by MicroRNA]. Zhongguo Fei Ai Za Zhi 2014;17:741-9. [PMID: 25342041 DOI: 10.3779/j.issn.1009-3419.2014.10.06] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Lv J, Hu L, Zhuo W, Zhang C, Zhou H, Fan L. Epigenetic alternations and cancer chemotherapy response. Cancer Chemother Pharmacol 2016;77:673-84. [DOI: 10.1007/s00280-015-2951-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
97 Felgueiras J, Fardilha M. Phosphoprotein phosphatase 1-interacting proteins as therapeutic targets in prostate cancer. World J Pharmacol 2014; 3(4): 120-139 [DOI: 10.5497/wjp.v3.i4.120] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Seven M, Karatas OF, Duz MB, Ozen M. The role of miRNAs in cancer: from pathogenesis to therapeutic implications. Future Oncology 2014;10:1027-48. [DOI: 10.2217/fon.13.259] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
99 Kim ES, Choi JY, Hwang SJ, Bae IH. Hypermethylation of miR-205-5p by IR Governs Aggressiveness and Metastasis via Regulating Bcl-w and Src. Mol Ther Nucleic Acids 2019;14:450-64. [PMID: 30743214 DOI: 10.1016/j.omtn.2018.12.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
100 Mittal A, Chitkara D, Behrman SW, Mahato RI. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials. 2014;35:7077-7087. [PMID: 24836307 DOI: 10.1016/j.biomaterials.2014.04.053] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 12.4] [Reference Citation Analysis]
101 Ferrari E, Gandellini P. Unveiling the ups and downs of miR-205 in physiology and cancer: transcriptional and post-transcriptional mechanisms. Cell Death Dis 2020;11:980. [PMID: 33191398 DOI: 10.1038/s41419-020-03192-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
102 Mondal G, Almawash S, Chaudhary AK, Mahato RI. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. Mol Pharm 2017;14:3121-33. [PMID: 28719220 DOI: 10.1021/acs.molpharmaceut.7b00355] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
103 De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97-110. [PMID: 23344542 DOI: 10.1038/nrc3447] [Cited by in Crossref: 1460] [Cited by in F6Publishing: 1422] [Article Influence: 182.5] [Reference Citation Analysis]
104 Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D’Alessandro A, Zolla L, Finazzi Agrò A. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2013;32:797-802. [PMID: 22469988 DOI: 10.1038/onc.2012.100] [Cited by in Crossref: 114] [Cited by in F6Publishing: 122] [Article Influence: 12.7] [Reference Citation Analysis]
105 Puhr M, Hoefer J, Schäfer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, Culig Z. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 2012;181:2188-201. [PMID: 23041061 DOI: 10.1016/j.ajpath.2012.08.011] [Cited by in Crossref: 152] [Cited by in F6Publishing: 149] [Article Influence: 16.9] [Reference Citation Analysis]
106 Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S, Blandino G. MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Ther 2014;2:16. [PMID: 26056584 DOI: 10.1186/2052-8426-2-16] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
107 Ors-Kumoglu G, Gulce-Iz S, Biray-Avci C. Therapeutic microRNAs in human cancer. Cytotechnology. 2019;71:411-425. [PMID: 30600466 DOI: 10.1007/s10616-018-0291-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 12.5] [Reference Citation Analysis]
108 Karnuth B, Dedy N, Spieker T, Lawlor ER, Gattenlöhner S, Ranft A, Dirksen U, Jürgens H, Bräuninger A. Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion. PLoS One 2014;9:e93067. [PMID: 24667836 DOI: 10.1371/journal.pone.0093067] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
109 Martinez EC, Lilyanna S, Wang P, Vardy LA, Jiang X, Armugam A, Jeyaseelan K, Richards AM. MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease. J Mol Cell Cardiol 2017;112:27-39. [PMID: 28865712 DOI: 10.1016/j.yjmcc.2017.08.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
110 Samuel P, Pink RC, Caley DP, Currie JM, Brooks SA, Carter DR. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells. Tumour Biol 2016;37:2565-73. [PMID: 26386726 DOI: 10.1007/s13277-015-4081-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
111 Lin LF, Li YT, Han H, Lin SG. MicroRNA-205-5p targets the HOXD9-Snail1 axis to inhibit triple negative breast cancer cell proliferation and chemoresistance. Aging (Albany NY) 2021;13:3945-56. [PMID: 33428601 DOI: 10.18632/aging.202363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Wu K, Yang Y, Zhao J, Zhao S. BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10. Cancer Lett 2016;371:125-33. [PMID: 26655271 DOI: 10.1016/j.canlet.2015.11.031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
113 Zhang S, Li D, Jiao GJ, Wang HL, Yan TB. miR-185 suppresses progression of Ewing's sarcoma via inhibiting the PI3K/AKT and Wnt/β-catenin pathways. Onco Targets Ther 2018;11:7967-77. [PMID: 30519038 DOI: 10.2147/OTT.S167771] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
114 Hanin G, Soreq H. Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes. Front Mol Neurosci 2011;4:28. [PMID: 22007158 DOI: 10.3389/fnmol.2011.00028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
115 Cho HJ, Liu G, Jin SM, Parisiadou L, Xie C, Yu J, Sun L, Ma B, Ding J, Vancraenenbroeck R, Lobbestael E, Baekelandt V, Taymans JM, He P, Troncoso JC, Shen Y, Cai H. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet 2013;22:608-20. [PMID: 23125283 DOI: 10.1093/hmg/dds470] [Cited by in Crossref: 139] [Cited by in F6Publishing: 140] [Article Influence: 15.4] [Reference Citation Analysis]
116 Qin RF, Zhang J, Huo HR, Yuan ZJ, Xue JD. MiR-205 mediated APC regulation contributes to pancreatic cancer cell proliferation. World J Gastroenterol 2019; 25(28): 3775-3786 [PMID: 31391772 DOI: 10.3748/wjg.v25.i28.3775] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
117 Kim JH, Lee H, Shin EA, Kim DH, Choi JB, Kim SH. Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression. Expert Opin Ther Targets 2017;21:911-20. [PMID: 28816549 DOI: 10.1080/14728222.2017.1369044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
118 Díaz-Martín J, Díaz-López A, Moreno-Bueno G, Castilla MÁ, Rosa-Rosa JM, Cano A, Palacios J. A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J Pathol. 2014;232:319-329. [PMID: 24122292 DOI: 10.1002/path.4289] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
119 Wu C, Miao C, Tang Q, Zhou X, Xi P, Chang P, Hua L, Ni H. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression. J Cell Mol Med 2020;24:2098-108. [PMID: 31876385 DOI: 10.1111/jcmm.14050] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
120 Balázs K, Antal L, Sáfrány G, Lumniczky K. Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients. J Pers Med 2021;11:296. [PMID: 33924671 DOI: 10.3390/jpm11040296] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
121 Preusse M, Schughart K, Pessler F. Host Genetic Background Strongly Affects Pulmonary microRNA Expression before and during Influenza A Virus Infection. Front Immunol 2017;8:246. [PMID: 28377766 DOI: 10.3389/fimmu.2017.00246] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
122 Rotblat B, Melino G, Knight RA. NRF2 and p53: Januses in cancer? Oncotarget 2012;3:1272-83. [PMID: 23174755 DOI: 10.18632/oncotarget.754] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 8.8] [Reference Citation Analysis]
123 Rufini A, Melino G. Cell death pathology: the war against cancer. Biochem Biophys Res Commun 2011;414:445-50. [PMID: 21971555 DOI: 10.1016/j.bbrc.2011.09.110] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
124 Khan MI, Hamid A, Adhami VM, Lall RK, Mukhtar H. Role of epithelial mesenchymal transition in prostate tumorigenesis. Curr Pharm Des 2015;21:1240-8. [PMID: 25506896 DOI: 10.2174/1381612821666141211120326] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
125 Korourian A, Roudi R, Shariftabrizi A, Madjd Z. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med (Maywood). 2017;242:1842-1847. [PMID: 28836853 DOI: 10.1177/1535370217728460] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
126 Biersack B. Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs. Noncoding RNA Res 2017;2:1-17. [PMID: 30159416 DOI: 10.1016/j.ncrna.2016.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
127 Aghdam SG, Ebrazeh M, Hemmatzadeh M, Seyfizadeh N, Shabgah AG, Azizi G, Ebrahimi N, Babaie F, Mohammadi H. The role of microRNAs in prostate cancer migration, invasion, and metastasis. J Cell Physiol 2019;234:9927-42. [PMID: 30536403 DOI: 10.1002/jcp.27948] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
128 Rizzo M. Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs. Biochim Biophys Acta Rev Cancer 2021;1875:188481. [PMID: 33217485 DOI: 10.1016/j.bbcan.2020.188481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
129 Bian X, Shen Y, Zhang G, Gu C, Cai Y, Wang C, Zhu Y, Zhu Y, Zhang H, Dai B, Ye D. Expression of dicer and its related miRNAs in the progression of prostate cancer. PLoS One 2015;10:e0120159. [PMID: 25768283 DOI: 10.1371/journal.pone.0120159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
130 Zhang X, Zhang Y, Liu X, Fang A, Li P, Li Z, Liu T, Yang Y, Du L, Wang C. MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. PLoS One 2015;10:e0143441. [PMID: 26599571 DOI: 10.1371/journal.pone.0143441] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
131 Suresh R, Sethi S, Ali S, Giorgadze T, Sarkar FH. Differential Expression of MicroRNAs in Papillary Thyroid Carcinoma and Their Role in Racial Disparity. J Cancer Sci Ther 2015;7:145-54. [PMID: 26380656 DOI: 10.4172/1948-5956.1000340] [Cited by in Crossref: 4] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
132 He A, Chen Z, Mei H, Liu Y. Decreased expression of LncRNA MIR31HG in human bladder cancer. CBM 2016;17:231-6. [DOI: 10.3233/cbm-160635] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
133 Sun M, Zhang Q, Yang X, Qian SY, Guo B. Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism. Mol Cancer Ther 2016;15:2086-95. [PMID: 27458137 DOI: 10.1158/1535-7163.MCT-16-0095] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
134 Kumar A, Ghosh S, Chandna S. Evidence for microRNA-31 dependent Bim-Bax interaction preceding mitochondrial Bax translocation during radiation-induced apoptosis. Sci Rep 2015;5:15923. [PMID: 26514984 DOI: 10.1038/srep15923] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
135 Zabolotneva AA, Zhavoronkov AA, Shegay PV, Gaifullin NM, Alekseev BY, Roumiantsev SA, Garazha AV, Kovalchuk O, Aravin A, Buzdin AA. A systematic experimental evaluation of microRNA markers of human bladder cancer. Front Genet. 2013;4:247. [PMID: 24298280 DOI: 10.3389/fgene.2013.00247] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
136 Anil D, Caykoylu EU, Sanli F, Gambacorta N, Karatas OF, Nicolotti O, Algul O, Burmaoglu S. Synthesis and biological evaluation of 3,5-diaryl-pyrazole derivatives as potential antiprostate cancer agents. Arch Pharm (Weinheim) 2021;:e2100225. [PMID: 34467575 DOI: 10.1002/ardp.202100225] [Reference Citation Analysis]
137 Konoshenko M, Laktionov P. The miRNAs involved in prostate cancer chemotherapy response as chemoresistance and chemosensitivity predictors. Andrology 2021. [PMID: 34333834 DOI: 10.1111/andr.13086] [Reference Citation Analysis]
138 Li S, Wang C, Liu X, Hua S, Liu X. The roles of AXIN2 in tumorigenesis and epigenetic regulation. Fam Cancer 2015;14:325-31. [PMID: 25504512 DOI: 10.1007/s10689-014-9775-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
139 Konoshenko MY, Laktionov PP. MiRNAs and radical prostatectomy: Current data, bioinformatic analysis and utility as predictors of tumour relapse. Andrology 2021;9:1092-107. [PMID: 33638886 DOI: 10.1111/andr.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Wang X, Yu M, Zhao K, He M, Ge W, Sun Y, Wang Y, Sun H, Hu Y. Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2. Cell Death Dis. 2016;7:e2517. [PMID: 27929537 DOI: 10.1038/cddis.2016.412] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
141 Liu Q, Ran R, Wu Z, Li X, Zeng Q, Xia R, Wang Y. Long Non-coding RNA X-Inactive Specific Transcript Mediates Cell Proliferation and Intrusion by Modulating the miR-497/Bcl-w Axis in Extranodal Natural Killer/T-cell Lymphoma. Front Cell Dev Biol 2020;8:599070. [PMID: 33364236 DOI: 10.3389/fcell.2020.599070] [Reference Citation Analysis]
142 Zhang G, Tian X, Li Y, Wang Z, Li X, Zhu C. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1. Biomedicine & Pharmacotherapy 2018;97:736-44. [DOI: 10.1016/j.biopha.2017.10.163] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]